• CD20 (188-196) peptide (TFA removed)

CD20 (188-196) peptide (TFA removed)

Not For Human Use, Lab Use Only.

Cat.#: 319703

Size:

Special Price 122.0 USD

Availability: 1-2 weeks
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    CD20 (188-196) peptide (TFA removed)
  • Documents
  • Sequence Shortening
    H-SLFLGILSV-OH
  • Sequence
    H-Ser-Leu-Phe-Leu-Gly-Ile-Leu-Ser-Val-OH
  • Length (aa)
    9
  • Peptide Purity (HPLC)
    95.4%
  • Molecular Formula
    C46H77N9O12
  • Molecular Weight
    948.15
  • PubChem CID
    440962825
  • Source
    Synthetic
  • Form
    Powder
  • Description
    CD20 (188-196) plays a significant role in research focused on generating cytotoxic T lymphocytes and stimulating CTL responses against B cell-related diseases. The production of these specific T cells and IFN-γ is measured using ELISPOT assays. CD20 (188-196) has been recognized as a highly immunogenic peptide that is restricted by HLA-A2. Research findings suggest that CD20 (188-196) could be crucial in immunotherapeutic approaches, especially in developing vaccines against certain types of blood cancers. Additionally, CD20 (188-196) is utilized in cell therapy research as a target for T cell receptors. T cells are modified in vivo to express specific T cell receptors and these modified cells are then introduced into patients with B cell cancers. This modification enables the T cells to recognize and target malignant B cells, providing a therapeutic strategy for treating these cancers.
  • Storage Guidelines
    Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides
  • References
    • Jahn L, van der Steen DM, Hagedoorn RS, et al. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies. Oncotarget. 2016;7(47):77021-77037. doi:10.18632/oncotarget.12778
  • About TFA salt

    Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

    TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

    TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

    In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.

  • Molar Concentration Calculator

  • Dilution Calculator

  • Percent Concentration Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight

Peptide Services: NovoPro's peptide synthesis services include standard chemical peptide synthesis, peptide modification, peptide libraries, and recombinant peptide expression.

Standard Peptide Synthesis: NovoPro offers quality peptides at the most competitive prices in the industry, starting at $3.20 per amino acid. NovoPro provides PepBox – Automatic Quote Tool for online price calculation.

Peptide Modifications: NovoPro offers a wide range of peptide modification services including isotope labeling (2H, 15N, and 13C), multiple disulfide bonds, multiple phosphorylations, KLH, BSA, ovalbumin, amidation, acetylation, biotin, FITC, etc.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"